Key Takeaways
- Revenue up 16.5% but margins fell: Crop care delivered 26.5% growth on price-led domestic gains and strong exports, while a ₹13 crore seed provision and cost inflation dragged EBITDA margin down ~330 bps YoY.
- Seeds business is the clear weak spot: Flat revenue, delayed monsoon liquidation, and an aging-based inventory provision of ₹13 crore hit the quarter; management calls it a challenging year and will reassess only by October.
- Export momentum is real but lumpy: International revenue crossed ₹100 crore in June, up 50.8% YoY, split evenly between volume and price; management warns this monthly run-rate cannot sustain month-on-month due to seasonality and phasing.
- Raw material relief is coming, slowly: Several input prices are cooling and supply chains have improved since December, but high-cost inventory will take until the latter part of Q2 to work through, delaying margin normalization.
- What to watch next quarter: Whether channel stocks liquidate as planned, the pace of seed inventory clearance, and how much of the raw material cost benefit actually flows to the bottom line once competitive pricing kicks in.
Crop Care: Price-Led Growth with Margin Pressure
- Domestic performance: 17.1% growth was overwhelmingly price-driven (~14% price, ~2-3% volume), with median price hikes of 4% to 5% taken to offset higher raw material costs. Volume growth came mainly from herbicides, which enter the crop cycle first.
- Channel stock build: The company consciously stocked the channel in Q1 to avoid missing liquidation opportunities in Q2; expects stocks to narrow to last year's level by H1 end.
- Margin squeeze: Crop care EBITDA improved to 9.5% from 8.1% YoY on operating leverage, but price hikes did not fully cover the raw material cost increase. Several input prices are now cooling, but high-cost inventory will take until the latter part of Q2 to unwind.
- Pricing outlook: Management flagged that final product prices are governed by cost of treatment to the farmer and competitive actions, not just input costs; some organizations have already indicated price reductions, and the company will take it product by product.
S Nagarajan: "The final product prices, we are more governed by the cost of treatment that we are able to provide to the farmer, the competitive actions that are there. So those have been more our guiding factors, we will have to see how the whole context plays out in Q2."
Seeds: A Challenging Year, Provision Taken Early
- Q1 disappointment: Seeds revenue was flat YoY; Q1 is normally the quarter where most of the heavy lifting is done, but delayed monsoon impacted liquidation, Paddy saw segment shifts, and Cotton demand was hit by delayed monsoon in Maharashtra and increased usage of illegal HT cotton seeds.
- ₹13 crore provision: Taken as a matter of prudence on inventory aging and stock liquidation, not a write-down. Some delay occurred due to a monsoon pause in June; sowing has since picked up, but unsold stocks will start coming back during Q2.
- Cotton addressable market shrinking: The quantum of cotton business is declining year-on-year because illegal cotton proliferation is shrinking the market available to organized players.
- Diggaz a bright spot: The Cotton hybrid launched last year in Punjab and Rajasthan grew from ~20,000 packets to an expected ~1.75 lakh packets this year.
- Full clarity only by October: Management will need to see how Q2 liquidation progresses before giving a full-year outlook and deciding on any further provisions.
Sanjiv Lal: "I think it is going to be a challenging year for us. Normally, Q1 is the quarter where most of the heavy lifting is done. And based on the way the season has progressed in Q1, as a matter of prudence, we have factored in certain provisions. We'll really need to see how Q2 goes before we are able to give a full year's outlook."
International Business: Strong Quarter, Cautious on Sustainability
- 50.8% YoY growth: Driven equally by volume (~25-26%) and price; demand for most products remains encouraging. The ₹100 crore June milestone was a good achievement but management cautioned it cannot happen month-on-month due to season and customer phasing.
- Product-specific dynamics: Good off-take for most products including Acephate; Hexaconazole volumes were lower because it is not the season for the key market, expected to look good towards Q2 and Q3. Metribuzin sales should pick up from Q2, with the plant running at capacity towards end of Q2.
- Pendimethalin tightness: The stockout situation from Q4 FY22 persists; one key starting material remains fairly tight, managed with some local supplies. Full normalization expected only towards the end of the calendar year.
- Formulation mix ambition: The company is working to increase the share of formulations in international business; Acephate formulation exports to Brazil start Q2, and Metribuzin formulated product in Brazil is picking up well. Management sees 20-24% formulation share as acceptable even as the overall export portfolio grows, because it tends to give more opportunities in more markets.
- Price risk flagged: Management gave a clear heads-up that prices are tending to be on the higher side; once they soften, revenues may look lower even if volumes remain.
Sanjiv Lal: "I would like to just mention that the prices are tending to be on the higher side. So once the prices soften, while the volumes may still be there, the revenues may start looking lower because of the price changes."
Supply Chain & Raw Materials: Turning the Corner
- Improvement since December: Supply chain conditions are "a lot more sanguine" than at December '21 end; raw material prices are coming down for quite a few inputs, and logistic challenges and fuel costs have eased somewhat.
- Local sourcing initiative: A local partner has been identified to supply raw material for one key product, aimed at lowering dependence on China and avoiding Pendimethalin-like supply disruptions. Cost-wise we may not see material impact, but it helps secure raw materials in a timely manner.
- Margin normalization delayed: High-cost inventory will progressively unwind by end of Q2; at a weighted average level, the company expects to be in a much more comfortable position on margins by then. The benefit from fresh, lower-cost raw material will depend on how realizations move from a competitive standpoint.
- Other expenses elevated: Freight costs (ocean and inland) are volume-linked and also impacted by steep inflation on diesel and ocean freight, driving the sharp increase in other expenses. Some components are variable and may reduce going forward, but this depends on external factors.
S Nagarajan: "On the supply chain front, I think, if you compare between, let's say, December end, December '21 end and June '22 end certainly we could say that things are looking a lot more sanguine than what they were at December end."
Strategic Initiatives: Registration Progress & Portfolio Expansion
- Brazil Acephate registration: Obtained registration for all 27 states in Brazil for Acephate formulation; shipments expected to commence from Q2.
- New product launches: Two new herbicides for Cotton and Paddy commercially launched; three new Paddy hybrids and a Tomato hybrid launched during the quarter.
- Contract manufacturing push: Two new contracts signed in Q4 FY22; a dedicated line of business has been created with a team in place and backend R&D support. Quantum may not be material in the near term but reflects renewed focus on scaling up.
- PEKK restart: After very little business for two years, the company has received positive indications of some requirement towards Q4; plant overhauling has started in anticipation, though no order is yet in hand.
- Biotech pipeline: Received state NOCs from Haryana and Karnataka for conducting BRL trials for insect resistance and herbicide tolerant Cotton, and Maize GM events; awaiting final regulatory approval, with hope to commence trials this financial year.
- CAPEX focus: Overall CAPEX of ₹250 crore for the year, with immediate focus on commissioning a multipurpose plant later in the year and commercial scale of one new technical (Difenoconazole). A new product from the multipurpose plant is expected towards the latter part of the year.
Sanjiv Lal: "We've now got some positive indication on some movements that we expecting towards Q4. So in anticipation of getting the PEKK plant back on stream, we have started the overhauling of the plant so that we are ready by the end of the year for getting the plant restarted, because there is some silver lining that we see in terms of getting back into production for PEKK."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Channel stock normalization | Channel stocks to narrow down closer to last year's level | By H1 end |
| Margin normalization | High-cost inventory unwound; more comfortable position at weighted average level | Latter part of Q2 |
| Metribuzin capacity | Plant running at capacity; inventory worked off | Towards end of Q2 |
| Pendimethalin normalization | Situation fully normalized | Towards end of calendar year |
| Acephate Brazil shipments | Formulation exports to commence | Q2 onwards |
| PEKK restart | Plant back on stream, subject to orders materializing | End of financial year |
| Seeds provision reassessment | Decision on further provisions after clarity on liquidation | By October |
| BRL trials commencement | Subject to final regulatory approval | This financial year |
| Multipurpose plant product launch | New product from new plant | Latter part of this year |
| Export revenue mix target | Exports at ~40% of revenues (from 33-34% currently) | 3-4 years down the line |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue | ₹863 cr, +16.5% YoY |
| EBITDA | ₹113 cr, vs ₹122 cr in Q1 FY22 |
| EBITDA margin | 13.1%, lower by 330 bps YoY |
| Profit after tax | ₹67 cr, vs ₹82 cr in Q1 FY22 |
| PAT margin | 7.8%, vs 11.1% in Q1 FY22 |
| Crop care revenue growth | 26.5% YoY, 16.3% price growth and 10.2% volume growth |
| Domestic business revenue growth | 17.1% YoY, primarily price-led |
| International business revenue growth | 50.8% YoY, driven by both volume and value |
| Seeds business revenue | ₹267 cr |
| Seeds inventory provision | ₹13 cr recognized on aging-based provision |
| Domestic crop care price growth | ~14% YoY, volume growth ~2-3% |
| Export volume growth | ~25-26%, balance price growth |
| Export formulation mix | ~20% of export portfolio |
| Metribuzin capacity utilization | 55-60% |
| Pendimethalin capacity utilization | 70-75% |
| Acephate capacity utilization | flat out |
| Cotton hybrid Diggaz volume | 1.75 lakh packets, up from ~20,000 packets last year |
| Full-year capex guidance | ₹250 cr |